e-Projection provides a high quality KOL interview service

KOL interviews can be a great method to gain an expert insight in to, for example, an evolving therapeutic landscape, unmet needs or a new therapy class. However, in order to obtain rich insights, it would be necessarily that KOLs are recruited and conducted to a high standard. We are here to help you to […]


Come & join our team at Biopharma America

e-Projection is attending 2022 BioPharm America virtual! We will put you in touch with Japanese healthcare industry, and help you to enter the Japanese market. Discuss your business challenges with us to get the best possible & innovative solutions to optimize your strategies and drive business growth in the Japanese market. If your company has […]


e-Projection talked at USC Comparative International Healthcare Systems course

Thank you USC Healthcare Decision Analysis & Biopharmaceutical Marketing for the opportunity to participate in this fantastic course, Comparative International Healthcare Systems! During this lecture, our CEO Tosh Nagate discussed with the attendees about the pharmaceutical industry in Japan and the general aspects of the pharmaceutical market. He also talked in-depth about the most important aspects of the pharmaceutical industry […]


Thanks for meeting with e-Projection at BIO2022

We had an amazing time talking about the future of biotech and networking with great people at BIO2022.The BIO International Convention is the major US convention bringing together representatives of the Pharma and Biotech Industry. This year more than 13,000 participants from more than 3,800 companies met at the San Diego Convention Center for 4 […]


Chuikyo approved listing of 14 Drugs on May 25

A total of 14 drugs will newly join Japan’s NHI price list on May 25. Chugai’s Vabysmo (faricimab), the first bispecific antibody in ophthalmology, for neovascular age-related macular degeneration and diabetic macular edema, is carrying the highest peak sales outlook among them, at 32 billion yen. Bayer’s non-steroidal selective mineralocorticoid receptor antagonist, Kerendia (Finelenone) also […]


Looking forward to meeting old and new contacts at Bio in San Diego

e-Projection will be participating in Bio International Convention ! Meet with us at BIO 2022 in San Diego, June 13-16 ! This is the most important event to promote us as an ideal partner for all seeking opportunity in Japan. And face-to face partnering opportunities are essential to progress in biotech, encouraging us to expand […]


Chuikyo approved listing of 8 Drugs on April 20

8 new drugs will join the reimbursement price list in Japan on April 20. In the FY2022 Drug pricing reform, the Chuikyo introduced “the premium coefficient 0 (less than 50% degree of disclosure)”, which is a new rule to improve transparency of manufacturing costs used in the cost calculation method for newly priced products, particularly […]



We are excited to join BIO-Europe Spring. We had a tremendous turnout during the last year’s BIO-Europe Spring. This year, Bio Europe has become digital as it did last year, but this is still a great event! Meet us on March 28 to 31, our team will be very pleased to discuss with you all! […]


New Light on Fertility Treatments;
9 Drugs for Fertility Treatment to Be Listed in April

In line with the introducing health coverage for fertility treatments from next April, the Central Social Insurance Medical Council (Chuikyo) approved the NHI price list of nine drugs for  fertility treatments. Listing is scheduled for April 1. Health coverage for infertility treatment is one of the measures compiled by former Prime Minister Yoshihide Suga to improve Japan’s low […]


Do you know why e-Projection is your most preferred partner in Japan?

Here you can find our company presentation given by CEO, Tosh Nagate! You would understand why we must be your most preferred partner in Japan.     It’s always a pleasure meeting with international clients that want to learn more about the significant benefits of approaching the Japanese market. Simply put, Japan appreciates innovation from […]